Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 6/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18781288 | 0.87 | CYP2D6 (0.38) | CYP2D6CYP2C19HRH1 | |
| SCHEMBL9976595 | 0.84 | GBA1 (0.37) | CYP2D6CYP2C19HRH1ESR1ESR2 | |
| SCHEMBL27051226 | 0.84 | KDM1A (0.41) | CYP2D6CYP2C19ESR1ESR2KCNH2 | |
| SCHEMBL25488731 | 0.82 | GNAI3 (0.40) | CYP2D6CYP2C19HRH1HRH3 | |
| SCHEMBL20756860 | 0.81 | KCNH2 (0.37) | CYP2D6HRH1ESR1ESR2KCNH2 | |
| SCHEMBL25475916 | 0.81 | GNAI3 (0.42) | CYP2D6CYP2C19HRH3 | |
| SCHEMBL14685578 | 0.79 | GNAI3 (0.43) | — | |
| SCHEMBL21397315 | 0.79 | DRD2 (0.40) | — | |
| SCHEMBL15837588 | 0.79 | DRD2 (0.40) | — | |
| SCHEMBL16980431 | 0.79 | DRD2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | CYP2D6 3436/4885CYP2C19 3974/4885HRH1 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.